Raymond James Financial’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$463K Sell
18,485
-21,597
-54% -$547K ﹤0.01% 4604
2026
Q2
$1.02M Sell
40,082
-12,595
-24% -$298K ﹤0.01% 3978
2026
Q1
$1.19M Buy
52,677
+35,121
+200% +$781K ﹤0.01% 3740
2025
Q4
$454K Buy
+17,556
New +$417K ﹤0.01% 4334
2025
Q3
– Sell
-90,108
Closed -$2.15M – 6231
2025
Q2
$2.15M Buy
90,108
+76,411
+558% +$1.93M ﹤0.01% 3028
2025
Q1
$340K Buy
13,697
+3,598
+36% +$86.1K ﹤0.01% 4143
2024
Q4
$190K Buy
+10,099
New +$177K ﹤0.01% 4416

Other funds holding PCRX

Raymond James Financial's PCRX Position: Q3 2026 in Review

Raymond James Financial reduced its Pacira BioSciences (PCRX) stake by 54% in Q3 2026, selling an estimated $547K and leaving 18,485 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #4604.

Raymond James Financial first reported a position in PCRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.15M in Q2 2025. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Raymond James Financial held 18,485 shares of Pacira BioSciences worth $463K as of Q3 2026.
  • Raymond James Financial sold 21,597 Pacira BioSciences shares in Q3 2026, an estimated $547K.
  • Pacira BioSciences made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4604 holding.
  • Raymond James Financial first reported a position in Pacira BioSciences in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Pacira BioSciences position peaked at $2.15M in Q2 2025.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.